Cumberland Pharmaceuticals (CPIX) closed at $4.95 on October 27, 2026, up 13.8% from the previous close, on volume of 514,859 shares (30-day average 65,024).
Data as of October 27, 2026.
At a glance: stocks gapping down premarket
Seeking Alpha News (Tue, 27-Oct 7:26 AM ET)
Cumberland announces ifetroban NDA filing plan after shares plummet
Seeking Alpha News (Mon, 26-Oct 6:50 PM ET)
Cumberland to Submit NDA for Ifetroban DMD Therapy
TipRanks (Mon, 26-Oct 4:57 PM ET)
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
PRNewswire (Mon, 26-Oct 4:41 PM ET)
Market Chameleon (Mon, 26-Oct 7:04 AM ET)
Cumberland Reports Positive Phase 2a Ifetroban Safety Results
TipRanks (Fri, 23-Oct 5:29 PM ET)
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
PRNewswire (Fri, 23-Oct 4:12 PM ET)
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
PRNewswire (Fri, 23-Oct 9:06 AM ET)
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
PRNewswire (Mon, 19-Oct 4:07 PM ET)
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
PRNewswire (Tue, 4-Aug 5:06 PM ET)
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Cumberland Pharmaceuticals trades on the NASDAQ stock market under the symbol CPIX.
As of October 28, 2026, CPIX stock price climbed to $5.09 with 61,499 million shares trading.
CPIX has a beta of 1.62, meaning it tends to be more sensitive to market movements. CPIX has a correlation of 0.03 to the broad based SPY ETF.
CPIX has a market cap of $76.26 million. This is considered a Micro Cap stock.
In the last 3 years, CPIX traded as high as $9.28 and as low as $1.04.
The top ETF exchange traded funds that CPIX belongs to (by Net Assets): VTI, VXF, DFAS, DFMC, IWC.
CPIX has outperformed the market in the last year with a return of +106.6%, while the SPY ETF gained +13.7%. However, in the most recent history, CPIX shares have underperformed the stock market with its stock returning -27.6% in the last 3 month period and -29.0% for the last 2 week period, while SPY has returned +4.7% and -0.8%, respectively.
CPIX support price is $4.56 and resistance is $5.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPIX shares will trade within this expected range on the day.
